A syndicate of new investors led by SV Life Sciences, Clarus Ventures, HBM BioVentures and HBM BioCapital has invested SFr 50m in ESBATech AG alongside existing investors. The series B financing is aimed at further developing the company's lead product, ESBA105, an antibody fragment candidate.
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater